AnaptysBio, Inc. (ANAB)

NASDAQ | Royalty Company | Biotech, immunology, royalty management
Intro rate Introductory pricing for early customers through June 30 — the same full analysis at a lower rate while we refine delivery.
Free
No email, no account, no signup.
Pulling latest news for AnaptysBio, Inc.…
Bull
Bear
Preliminary read — single AI model with live web search. The deep report cross-checks four models and more sources.
Intro rate Introductory pricing for early customers through June 30 — the same full analysis at a lower rate while we refine delivery.

Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.

Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – $4.99 $1.25
Order analysis – $4.99 $1.25

Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.

Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Royalty Company
Sector
Biotech, immunology, royalty management
Market Cap
$1.6B
We're already tracking AnaptysBio, Inc. — here are the latest events we've registered

Recent News

  • On May 11, 2026, AnaptysBio reported its first-quarter financial results and announced the completion of the spin-off of its biopharma operations into First Tracks Biotherapeutics. The company transitioned to a royalty-focused business model, exclusively managing collaborations for Jemperli with GSK and imsidolimab with Vanda Pharmaceuticals. This restructuring aims to separate the company's development pipeline from its stable royalty assets.
Want to know how this news affects AnaptysBio, Inc.? Order the analysis.
Order analysis – $4.99 $1.25

What you get

A complete express analysis — not just a signal. Delivered as a webpage in your account.

  • Signal: BUY / HOLD / SELL — with clear reasoning
  • Sentiment score 1–10 based on news, reports, and market data
  • Risk score 1–10 (dilution, jurisdiction, execution)
  • Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
  • Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
  • Upcoming catalysts with dates
  • Sources: news, filings, market data, and investor forums
  • Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of AnaptysBio, Inc. will be delivered in the same format.

Sample analyses in the same sector

Click to see what a complete analysis looks like.

Viper Energy, Inc.
VNOM
HOLD
Black Stone Minerals, L.P.
BSM
-
Nations Royalty Corp.
NRC
-
Kimbell Royalty Partners, LP
KRP
-
Natural Resource Partners L.P.
NRP
-
Order analysis – $4.99 $1.25
Not satisfied? Get your money back within 7 days — no questions asked.
AnaptysBio, Inc. (ANAB)
Fresh analysis on demand
Buy express analysis – $4.99 $1.25
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.